Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.

Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.

With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?

Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.